These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 18075506)

  • 1. Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptoms.
    Pimentel H; Wald M; Niederberger C
    Int J Impot Res; 2008; 20(2):145-9. PubMed ID: 18075506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men.
    Gales BJ; Gales MA
    Ann Pharmacother; 2008 Jan; 42(1):111-5. PubMed ID: 18094344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study.
    Zumbé J; Porst H; Sommer F; Grohmann W; Beneke M; Ulbrich E
    Eur Urol; 2008 Jul; 54(1):204-10. PubMed ID: 18395326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
    Roumeguère T; Zouaoui Boudjeltia K; Hauzeur C; Schulman C; Vanhaeverbeek M; Wespes E
    BJU Int; 2009 Aug; 104(4):511-7. PubMed ID: 19239452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition.
    Fusco F; Razzoli E; Imbimbo C; Rossi A; Verze P; Mirone V
    BJU Int; 2010 Jun; 105(12):1634-9. PubMed ID: 20553468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review.
    Rambhatla A; Kovanecz I; Ferrini M; Gonzalez-Cadavid NF; Rajfer J
    Int J Impot Res; 2008; 20(1):30-4. PubMed ID: 17673932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily use of PDE5-inhibitors: the road to happiness?
    Gratzke C
    Eur Urol; 2008 Jul; 54(1):28-30. PubMed ID: 18372095
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors.
    Uckert S; Stief CG
    Handb Exp Pharmacol; 2011; (204):307-22. PubMed ID: 21695646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.
    Porst H; McVary KT; Montorsi F; Sutherland P; Elion-Mboussa A; Wolka AM; Viktrup L
    Eur Urol; 2009 Oct; 56(4):727-35. PubMed ID: 19409693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction.
    Seftel A
    J Urol; 2005 Nov; 174(5):1940-1. PubMed ID: 16217354
    [No Abstract]   [Full Text] [Related]  

  • 12. Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds.
    Wong P; Lawrentschuk N; Bolton DM
    Curr Opin Urol; 2009 Jan; 19(1):7-12. PubMed ID: 19057210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial comment on: Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.
    Volpe A
    Eur Urol; 2009 Oct; 56(4):735-6. PubMed ID: 19409694
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
    Ali ST
    Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors.
    Hellstrom WJ
    Int J Clin Pract; 2007 Sep; 61(9):1547-54. PubMed ID: 17655683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial: K. T. McVary, W. Monnig, J. L. Camps, Jr., J. M. Young, L. J. Tseng and G. van den Ende. J Urol 2007; 177: 1071-1077.
    Ponholzer A; Rauchenwald M; Madersbacher S
    J Urol; 2007 Sep; 178(3 Pt 1):1121-2; author reply 1122-3. PubMed ID: 17640682
    [No Abstract]   [Full Text] [Related]  

  • 17. PDE5 inhibitors beyond erectile dysfunction.
    Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
    Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction.
    Burnett AL; Strong TD; Trock BJ; Jin L; Bivalacqua TJ; Musicki B
    J Urol; 2009 Jan; 181(1):245-51. PubMed ID: 19013603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial comment on: comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study.
    Salonia A
    Eur Urol; 2008 Jul; 54(1):211-2. PubMed ID: 18395330
    [No Abstract]   [Full Text] [Related]  

  • 20. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications.
    Bella AJ; Deyoung LX; Al-Numi M; Brock GB
    Eur Urol; 2007 Oct; 52(4):990-1005. PubMed ID: 17646047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.